Walmart’s latest brand and logo update has left some social media users baffled. On Jan. 13, the company announced in a press release on its website that it was launching a “comprehensive ...

After going viral for his pre-kick routine, Washington Commanders' kicker Zane Gonzalez is opening up about his struggle with OCD that he says he’s been managing for years. NBC’s Sam Brock ...

Want to brand your business without breaking the bank? The best free logo maker will be an essential tool in your marketing kit - and after testing these completely free logo designers ...

Johnson & Johnson (NYSE:JNJ) traded flat in the premarket on Wednesday after the pharma giant exceeded Street forecasts for Q4 2024, mainly due to its Innovative Medicine unit, while its MedTech ...

Overall, Johnson & Johnson had a strong quarter, continuing to expand its product pipeline and positioning itself well amid market fluctuations. Johnson & Johnson is a diversified healthcare giant ...

Speaker Mike Johnson, R-La., was asked about President Trump's pardons for those involved in the Capitol riot, including some for those convicted of violent crimes. Johnson described the ...

On Tuesday, the Food and Drug Administration (FDA) approved Johnson & Johnson’s nasal spray, Spravato (esketamine), to treat major depressive disorder. Oral antidepressants are the most common ...

Johnson & Johnson (NYSE:JNJ) is scheduled to announce Q4 earnings results on Wednesday, January 22nd, before market open. Analysts expect a profit per share of $2.02, which is a decline of 11.8% ...

Below is Validea's guru fundamental report for JOHNSON & JOHNSON (JNJ). Of the 22 guru strategies we follow, JNJ rates highest using our Shareholder Yield Investor model based on the published ...

Also Read: Like Bristol-Myers Squibb And AbbVie, Johnson & Johnson Seeks To Bolster Neuropsychiatric Portfolio With $15 Billion Deal This approval, granted following FDA Priority Review ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Johnson & Johnson (JNJ – Research Report), with a price target of $175.00. The company’s shares closed ...